Browse by author
Lookup NU author(s): Professor Michael Barnes
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Sativex (R) is one of the first cannabis-based medicines to undergo conventional clinical development and to be approved as a prescription medicine. It is an oromucosal spray that allows flexible, individualised dosing. Patients self titrate their overall dose and pattern of dosing according to their response to and tolerance of the medicine. This usually results in the administration of similar to 8 - 12 sprays/day. Each spray delivers tetrahydrocannabinol 2.7 mg and cannabidiol 2.5 mg, giving an approximate average dose of tetrahydrocannabinol 22 - 32 mg/day and cannabidiol 20 - 30 mg/day. Development has concentrated on the treatment of symptoms of multiple sclerosis, notably spasticity and neuropathic pain, as well as the treatment of neuropathic pain of other aetiologies. Positive results in placebo-controlled trials of the use of Sativex as an add-on therapy in these indications demonstrate that Sativex is efficacious and well tolerated in the treatment of these symptoms. Sativex has been approved for use in neuropathic pain due to multiple sclerosis in Canada. If ongoing studies replicate the results already observed, further approvals for the treatment of spasticity in multiple sclerosis and for neuropathic pain are likely.
Author(s): Barnes MP
Publication type: Review
Publication status: Published
Journal: Expert Opinion on Pharmacotherapy
Year: 2006
Volume: 7
Issue: 5
Pages: 607-615
ISSN (print): 1465-6566
ISSN (electronic): 1744-7666
URL: http://dx.doi.org/10.1517/14656566.7.5.607
DOI: 10.1517/14656566.7.5.607
